about
Challenge of cancer in the elderlyChanges in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelOptimal therapy of type 2 diabetes: a controversial challengeIn vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.Potentially inappropriate drug use in older people: a nationwide comparison of different explicit criteria for population-based estimates.Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.In vitro metabolism of specific CYP2D and CYP3A opioid substrates using rat liver S9 fractions and mass spectrometry reveal a severe metabolic impairment with increasing age.Use of antiarrhythmic drugs in elderly patientsClobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studiesAnesthetic Pharmacology and the Morbidly Obese Patient.Venlafaxine-induced orthostatic hypotension in a geriatric patient.Effect of age on the pharmacokinetics of polymorphic nimodipine in rats after oral administrationThe safety of ketoprofen in different ages.Estimating renal function to reduce the risk of adverse drug reactions.Geriatric conditions and the risk of adverse drug reactions in older adults: a review.Mast cells and the liver aging processSystematic review of anticholinergic risk scales in older adults.Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review.The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects.Primary glomerular diseases in the elderly.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from ten Phase I trials.Anticholinergics: theoretical and clinical overview.Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.Antibiothérapie du sujet âgé : On peut toujours mieux faire.Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research.High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.Potentially inappropriate medications: predictor for mortality in a cohort of community-dwelling older adults.Safety Profile of Artemether-Lumefantrine: A Cohort Event Monitoring Study in Public Health Facilities in Tanzania.Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.Post mortem toxicology in the elderly.Clinical pharmacology in everyday clinical care.Post-mortem toxicology in the elderly.Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures - accurate prediction of the human urinary excretory amounts.Adverse Drug reactions in an Ageing PopulaTion (ADAPT) study protocol: a cross-sectional and prospective cohort study of hospital admissions related to adverse drug reactions in older patients.Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery.Do FSH/LH ratio and gonadal hormone levels predict clinical improvement in postmenopausal schizophrenia women?Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females."Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology.
P2860
Q28069040-21ECD255-55BF-4FD9-BE8B-23704AF94F1BQ33574126-CFEEBFBE-9D47-403D-A9F6-16A945E5E2B3Q33577712-4001DAEA-C229-4E38-95C0-BA19937B75E2Q35746225-F7C52DF0-98F6-4389-83B7-B332F2AC949BQ35972257-8367B7A3-7DEA-4F58-BEFA-EB4299CF16D7Q35998552-35D82488-AC93-4D97-BBDB-7011CEC5CF91Q36070671-87ABD34A-209A-4E84-80D9-3D644F883F04Q36077245-662ADE0E-5107-40FC-9713-676C45A7ECDAQ36537180-85BAAFF6-DDAF-4649-BD4A-6595606DD992Q36697500-E16347BD-3E84-49F3-8D92-4120BC75D419Q37105268-393A8FBC-FE87-4DAE-AD70-017754D985C6Q37302182-731527BB-9525-4F10-B96C-15DC7E0A0D3BQ37369689-9E478B56-B050-4B48-A73C-D539A3703155Q38085223-2A97FA12-F2C3-414A-B26A-3B96D80D8FA9Q38085224-891CD5C3-E53C-4B0F-A8A9-91505CB9FD5EQ38089955-FDFB77A6-48C3-4F5E-B79B-2A40091AC1A4Q38093092-35B9A3D9-B5FF-4D3D-9298-8506DB89DD08Q38100753-38B3DA3C-C0F6-400C-95CB-97B127547494Q38187907-61FFE8B6-4881-4C35-9A4C-0CFF6998FEA0Q38416026-02EEF19E-D677-4230-976D-085910F878BFQ38463829-74257983-1FA9-46A1-9AEB-1B2249161801Q38544216-166AEC27-80FD-4C5B-AA81-181BE6A62E0BQ38612177-E0EEA3E5-02B0-4DC9-A955-E963657C5E63Q38769800-124FC960-8325-4C19-9906-C8B1A6ADE407Q38846045-A7E76FE3-2B98-4791-83BF-C6C89A377F2EQ38862567-EBF2CF7A-1FEC-4894-B3BA-4F2A3029DDDDQ38886942-3B24B80A-56E8-4DE4-BEEB-DCB6AC8242C0Q38937142-A654B1FC-4FD2-4120-80D7-39260026D4E3Q39008761-ADEBCEC9-DEA0-489F-BEF3-9262605A7FB1Q39941785-F7833302-E93A-47D8-BCB1-550A0B9947EAQ40672214-4A8B3C81-6FB0-4BED-85D9-21D4955D7201Q44409586-402EEACB-7E16-4FE0-87E8-D4939C55C3E9Q45142665-1C35CFF1-5907-4CB2-8D38-267EBDB50D81Q45716784-56275E3E-76A2-4173-8816-1CEF8ABA4CCCQ46561449-0F9834E0-462B-4AE1-A7FB-9F74A038B95EQ47101791-FEE570DC-0A46-45F2-B9CB-FF9C3114B7ACQ47376616-53CB2960-7C11-4688-8624-5608B4C024C2Q48587906-49D11723-A053-4D4A-9876-9DA3EDCC6421Q51152617-4641312F-EAB3-4E84-A173-5799B181995BQ51557998-6B2FC1FE-EB1B-42FF-920A-B7CF561E3C73
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Age-related changes in pharmacokinetics.
@en
Age-related changes in pharmacokinetics.
@nl
type
label
Age-related changes in pharmacokinetics.
@en
Age-related changes in pharmacokinetics.
@nl
prefLabel
Age-related changes in pharmacokinetics.
@en
Age-related changes in pharmacokinetics.
@nl
P1476
Age-related changes in pharmacokinetics.
@en
P2093
Shaojun Shi
Ulrich Klotz
P304
P356
10.2174/138920011796504527
P407
P577
2011-09-01T00:00:00Z